Title: Clindamycin's Role in Skin and Soft Tissue Infections
题目：克林霉素在皮肤和软组织感染中的作用
Author作者: Bryan Hayes
江利冰 译 肖锋 校

Clindamycin used to be a first-line agent for many SSTIs, particularly where MRSA was suspected. With growing resistance to staph species, the 2014 IDSA Guidelines recommend clindamycin as an option only in the following situations:
克林霉素以往作为很多皮肤软组织感染的一线用药，尤其是怀疑发生耐甲氧西林金黄色葡萄球菌感染时。随着金黄色葡萄球菌耐药性逐渐增加，2014年美国传染病协会指南推荐只有在下列情况下使用克林霉素：
•Nonpurulent SSTI (primarily strep species)
Mild - oral clindamycin
Moderate - IV clindamcyin
Severe, necrotizing infections - adjunctive clindamycin only with suspected or culture-confirmed strep pyogenes
非化脓性皮肤软组织感染（主要是链球菌属）
轻度—口服克林霉素
中度—静脉注射克林霉素
重度，坏死性感染—只有在怀疑或者培养确定是链球菌化脓的情况下加用克林霉素。

•Purulent SSTI (primarily staph species)
•化脓性皮肤软组织感染（主要是葡萄球菌属）
Clindamycin only recommended in moderate or severe cases if cultures yield MSSA
只有在培养确定的中重度金黄色葡萄球菌感染时推荐使用克林霉素。
* Clindamycin may be used if clindamycin resistance is <10-15% at the institution.
如果某医疗机构对克林霉素抵抗<10-15%，可以考虑使用克林霉素。
References
参考文献：
Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10-52. [PMID 24947530]